Acrobiosystems Co

Acrobiosystems Co Liabilities

The The Liabilities of Acrobiosystems Co (301080.SZ) as of Nov 11, 2026 is 351.90 M CNY. In the previous year, The Liabilities was 303.89 M CNY — a change of 15.80% (higher).

Liabilities

351.90 MCNY

YoY

15.80%

Last updated:

In 2025, Acrobiosystems Co's total liabilities amounted to 351.90 M CNY, a 15.80% difference from the 303.89 M CNY total liabilities in the previous year.

The Acrobiosystems Co Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
10.16 M CNY
Jan 1, 2019
16.12 M CNY
Jan 1, 2020
41.28 M CNY
Jan 1, 2021
78.84 M CNY
Jan 1, 2022
167.25 M CNY
Jan 1, 2023
225.22 M CNY
Jan 1, 2024
303.89 M CNY
Jan 1, 2025
351.90 M CNY
The Acrobiosystems Co Liabilities history
YEARLiabilitiesYoY
351.90 MCNY+15.80%
303.89 MCNY+34.93%
225.22 MCNY+34.66%
167.25 MCNY+112.15%
78.84 MCNY+90.98%
41.28 MCNY+156.04%
16.12 MCNY+58.67%
10.16 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Acrobiosystems Co's Liabilities

Acrobiosystems Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Acrobiosystems Co's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Acrobiosystems Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Acrobiosystems Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Acrobiosystems Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Acrobiosystems Co stock

The Liabilities of Acrobiosystems Co is 351.90 M CNY in 2025.

The Liabilities of Acrobiosystems Co changed from 303.89 M CNY to 351.90 M CNY, representing a 15.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Acrobiosystems Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Acrobiosystems Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Acrobiosystems Co